Alzheimer's Institute of America, Inc.

University of South Florida

Roskamp Research LLC

The Roskamp Institute

Daniel Paris

Michael J Mullan

Robert A Ivey, Iii

Gary Kompothecras

Michael Mullan

Terrence C Town

Chao Jin

Robert A Ivey

Robert A Iii Ivey

A composition comprising a therapeutically effective amount of at least one alkaloid combined with one or more non-alkaloid components, wherein the composition is configured to be administered to a subject.

Pharmaceutical composition

The present invention provides methods for reducing A&#x3b2; deposition, A&#x3b2; neurotoxicity and microgliosis in an animal or human afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the (R)-enantiomer of the dihydropyridine compound nilvadipine, also known as (&#x2212;)-nilvadipine, to the animal or human. Further provided are methods for reducing the risk of A&#x3b2; deposition, A&#x3b2; neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering (&#x2212;)-nilvadipine after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter.

Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer

Pharmaceutical compositions for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis

Provided are A&#x3b2; peptide fragments that are useful in inhibiting angiogenesis. Also provided are methods for the treatment of pathological or unwanted angiogenesis and conditions and diseases associated therewith by administering an effective amount of an A&#x3b2; fragment. In a particular embodiment, the peptide fragment includes the sequence HHQKLVFF.

Modulation of angiogenesis by A-beta peptide fragments

The present invention provides methods for reducing &#x3b2;-amyloid deposition, &#x3b2;-amyloid neurotoxicity and microgliosis in animals or humans afflicted with a cerebral amyloidogenic disease, such as Alzheimer's disease (AD), by administering therapeutically effective amounts of the dihydropyridine calcium channel antagonist, nilvadipine. The present invention also provides methods for diagnosing cerebral amyloidogenic diseases in animals or humans. Further provided are methods for reducing the risk of &#x3b2;-amyloid deposition, &#x3b2;-amyloid neurotoxicity and microgliosis in animals or humans suffering from traumatic brain injury by administering nilvadipine immediately after the traumatic brain injury and continuing treatment for a prescribed period of time thereafter. Finally, methods are provided for treating transplantable neuronal stem cells by administering nilvadipine to the neuronal stem cells prior to transplantation in the central nervous system of an animal or human afflicted with a cerebral amyloidogenic disease, such as AD.

Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis

There is provided a method of modifying vasoactivity by regulating a soluble A&#x3b2; pro-inflammatory pathway. Also provided is a method of modifying inflammatory reactions in microglia and neurons by regulating a soluble A&#x3b2; pro-inflammatory pathway. A method of treating patients with vascular disease by modifying an intracellular soluble A&#x3b2; pro-inflammatory pathway is also provided. A pharmaceutical composition consisting essentially of an effective amount of a soluble A&#x3b2; pro-inflammatory pathway regulator in a pharmaceutically effective carrier is also provided.

Modulation of the phospholipase A2 pathway as a therapeutic

The present invention provides methods and compositions for treating diseases and pathological conditions or processes mediated by undesired and/or uncontrolled angiogenesis (characterized as 'angiogenic diseases'), in particular cancer, by increasing the in vivo concentration of the A&#x3b2; peptide, within a patient suffering from such diseases, conditions or processes. The present invention also concerns diagnostic methods and kits for the detection and measurement of anti-angiogenic A&#x3b2; peptide activity in biological fluids and tissues. Such diagnostic methods and kits can be utilized to screen compounds for potential therapeutic activity in the treatment of angiogenic diseases such as Alzheimer's disease and cancer.

Growing community of inventors

Sarasota, FL, United States of America

Daniel Paris